65,437 trials
Acute Otitis Externa
Primary: Proportion of Patients With Clinical Cures at the Day 11 (TOC) Visit — 71.7; 33.3 percentage of participants
Prostate Cancer
Primary: Composite Progression-free Survival (cPFS) — 4.1; 6.7 months
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Carcinoma
Primary: Percentage of Participants With Progression-Free Survival at 6 Months (PFS-6) — 25.0 percentage of participants
Advanced Solid Tumors
Primary: Number of Participants With Drug-Related Adverse Events — 3; 6; 6; 0 participants
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Intraocular Pressure (IOP) in the Study Eye — 16.5; 16.7; 15.7; 16.1 Millimeters of Mercury (mmHg)
Metastatic Malignant Melanoma
Primary: Progression Free Survival (PFS) — 2.6; 1.7 months
Major Depressive Disorder
Primary: The Score on the Clinical Global Impression-Improvement (CGI-I) at Week 6 — 2.37; 2.82; 2.86 units on a scale
Healthy
Primary: Area Under the Curve 0 to Infinity (AUC0-∞) — 5200; 5090 nmol*h/L
PTSD · Sleep Disorders
Primary: CAPS Recurrent Distressing Dreams Item — -1.9; -1.7 scores on a scale
Malignant Solid Tumor
Primary: Part A: Pharmacokinetics - Dose-Normalized Area Under the Concentration Versus Time Curve of Paclitaxel From Time Zero to Infinity [AUC(0-∞)] in Cycle 1 — 29…
Breast Cancer · Metastatic Breast Cancer
Primary: Number of Participants With Adverse Events — 2; 7; 4; 6 participants
Healthy
Primary: Ethinylestradiol: Area Under the Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss) — 907; 932 pg*h/mL
Metastatic Renal Cell Carcinoma
Primary: Percentage of Participants With Objective Response (Objective Response Rate) — 5.1 percentage of participants
Diabetes Mellitus, Type 2
Primary: Change of Glycosilated Haemoglobin A1c (HbA1c) From Baseline After 12 Weeks of Treatment — 0.09; -0.43; -0.48; -0.63 percentage of HbA1c — p=<0.0001
Diagnostic Colonoscopy Screening
Primary: The Recovery Time — 0; 30 minute — p=< 0.001